HOME > 研究紹介 > 発表論文 > 2022年

研究紹介

発表論文 - 2022年

  1. Hamdy AK, Sakamoto T, Toma T, Sakamoto M, Abourehab MAS, Otsuka M, Fujita M, Tateishi H, and Radwan MO.
    New insights into the structural requirements of isatin-derived pro-apoptotic agents against acute myeloid leukemia.
    Pharmaceuticals 15: 1579, 2022.
  2. Ciftci H, Sever B, Ayan E, Can M, DeMirci H, Otsuka M, Tuyun AF, Tateishi H, and Fujita M.
    Identification of new L-heptanoylphosphatidyl inositol pentakisphosphate derivatives targeting the interaction with HIV-1 Gag by molecular modelling studies.
    Pharmaceuticals 15: 1255, 2022.
  3. Ciftci H, Sever B, Bayrak N, Yildiz M, Yildirim H, Tateishi H, Otsuka M, Fujita M, and Tuyun AF.
    In vitro cytotoxicity evaluation of plastoquinone analogues against colorectal and breast cancers along with in silico insights.
    Pharmaceuticals 15: 1266, 2022.
  4. Ulusoy NG, Emirdag S, Sozer E, Radwan MO, Ciftci H, Aksel M, Bolukbasi SS, Ozmen A, Yayli N, Karayildirim T, Alankus O, Tateishi H, Otsuka M, Fujita M, and Sever B.
    Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction.
    International Journal of Biological Macromolecules 222(Pt A): 1487-1489, 2022.
  5. Goler AMY, Jannuzzi AT, Bayrak N, Yildiz M, Yildirim H, Otsuka M, Fujita M, Radwan M, and Tuyun AF.
    In vitro and in silico study to assess toxic mechanisms of hybrid molecules of quinone-benzocaine as plastoquinone analogs in breast cancer cells.
    ACS Omega 7: 30250-30264, 2022.
  6. Yildirim H, Yildiz M, Bayrak N, Mataraci-Kara E, Ozbek-Celik B, Otsuka M, Fujita M, Radwan MO, and Tuyun AF.
    Natural-product-inspired design and synthesis of thiolated coenzyme Q analogs as promising agents against Gram-positive bacterial strains: insights into structure-activity relationship, activity profile, mode of action, and molecular docking.
    RSC Advances 12: 20507-20518, 2022.
  7. 牧野雄成、當眞嗣雅、立石大、藤田美歌子、大塚雅巳、片岡良友
    全身性強皮症の分子病態と治療薬創製
    Bio Clinica 37(9): 58-63, 2022.
  8. Toma T, Yamashita J, Radwan MO, Badran MM, Masunaga T, Kamo M, Koga R, Okamoto Y, Tateishi H, Otsuka M, and Fujita M.
    Tranilast-tyrosine hybrid molecule exhibits dual activity: Suppression of epithelial-mesenchymal transition and induction of cytotoxicity in cancer cells. Medicinal Chemistry Research 31: 1584-1593, 2022
  9. Toma T, Tateishi H, Kawakami K, Ali TFS, Kamo M, Monde K, Nakashima Y, Fujita M, and Otsuka M.
    Novel inhibitor for downstream targeting of transforming growth factor-β signaling to suppress epithelial to mesenchymal transition and cell migration.
    International Journal of Molecular Sciences 23: 5047, 2022.
  10. Yildirim H, Yildiz M, Bayrak N, Mataraci-Kara E, Radwan MO, Jannuzzi AT, Otsuka M, Fujita M, and Tuyun AF.
    Promising antibacterial and antifungal agents based on thiolated vitamin K3 analogs: Synthesis, bioevaluation, molecular docking.
    Pharmaceuticals 15: 586, 2022.
  11. Nakagawa R, Tateishi H, Radwan MO, Chinen T, Ciftci H, Iwamaru K, Baba M, Tominaga Y, Koga R, Toma T, Inoue J, Umezawa K, Fujita M, and Otsuka M.
    A new 1,2-naphthoquinone derivative with anti-lung cancer activity.
    Chemical & Pharmaceutical Bulletin 70: 477-482, 2022
  12. Ali TFS, Ciftci HI, Radwan MO, Roshdy E, Shawky AM, Abourehab MAS, Tateishi H, Otsuka M, and Fujita M.
    Discovery of azaindolin-2-one as a dual inhibitor of GSK3β and tau aggregation with potential neuroprotective activity.
    Pharmaceuticals 15: 426, 2022.
  13. Sever B, Ciftci H, DeMirci H, Sever H, Ocak F, Yulug B, Tateishi H, Tateishi T, Otsuka M, Fujita M, and Basak AN.
    Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis.
    International Journal of Molecular Sciences 23: 2400, 2022.
  14. Ciftci H, Sever B, Ocak F, Bayrak N, Yildiz M, Yildirim H, DeMirci H, Tateishi H, Otsuka M, Fujita M, and Tuyun AF.
    In Vitro and in silico study of analogs of plant product plastoquinone to be effective in colorectal cancer treatment.
    Molecules 27: 693, 2022.
  15. Ozdemir A, Ciftci H, Sever B, Tateishi H, Otsuka M, Fujita M, and Altintop MD.
    A new series of indeno[1,2-c]pyrazoles as EGFR TK inhibitors for NSCLC therapy.
    Molecules 27: 485, 2022.
  16. Hassan AN, Toma T, Ciftci H, Biswas T, Tahara Y, Radwan MO, Tateishi H, Fujita M, and Otsuka M.
    A vitamin D C/D ring-derived compound with cytotoxicity.
    Medicinal Chemistry Research 31:1120-1125, 2022
  17. Kawashima K, Hirota-Tsukimachi M, Toma T, Koga R, Iwamaru K, Kanemaru Y, Yanae M, Ahagon A, Nakamura Y, Anraku K, Tateishi H, Gohda J, Inoue J, Otsuka M, and Fujita M.
    Development of chimeric RANK with GST in the extracellular domain: Artificial switch in a membrane receptor.
    Chemical Biology & Drug Design 99: 573-584, 2022.